Effect on Survival after TAVR with PPM†1
severe PPM (indexed
EOA < 0.65 cm2/m2)
experienced a 20%
increase in mortality.1
iEOA < 0.85 cm2/m2 experienced a 44%
increase in heart failure hospitalizations.1
Moderate/severe PPM is independently associated with 2.3-fold increase in the risk of structural valve degeneration.2
The Evolut TAVR platform achieves large EOAs by having a valve design that reduces obstruction to the blood flowing through the annulus.
Predictors of Severe PPM1
Valve Sizes at Elevated Risk of PPM
†† TAV-in-SAV only
† The analysis set for this data included all patients enrolled in the registry between January 1, 2014, and March 31, 2017, and included all U.S. Medtronic and Edwards commercial valves.
© 2018 Medtronic. All rights reserved, Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. TM*Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. J Am Coll Cardiol. Published online September 23, 2018.
Flameng W, Herregods MC, Vercalsteren M, Herijgers P, Bogaerts K, Meuris B. Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves. Circulation. May 18, 2010;121(19):2123-2129.
Rogers T, et al. Choice of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Impacts Hemodynamics Differently According to Aortic Annular Size. Am J Cardiol.2017;119(6):900-904.